Login / Signup

Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis.

Manuela ColucciRaffaella LabbadiaMarina VivarelliFrancesca Diomedi CamasseiFrancesco EmmaLuca Dello Strologo
Published in: Pediatric nephrology (Berlin, Germany) (2019)
Ofatumumab may be a therapeutic option for post-transplant FSGS recurrence in patients who respond poorly to rituximab.
Keyphrases
  • free survival
  • diffuse large b cell lymphoma
  • hodgkin lymphoma
  • chronic lymphocytic leukemia
  • replacement therapy